Virtual Patient: Care of an Older Adult with Asthma During the COVID-19 Pandemic

In this patient simulation, you will evaluate and treat an older adult patient with asthma in the current setting of the COVID-19 pandemic. As the pandemic continues to evolve, you will make the best possible choices for therapy and continuation of therapy, including biologic therapies, given the potential logistical issues and limited resources available. You will become more adept at distinguishing between symptoms and signs of asthma compared with COVID-19, given the current information available. In addition, you will recommend and advise the patient on strategies to reduce exposure to COVID-19, including at home and workplace. 

This course is funded by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

  • Allergist/immunologists
  • Fellows-in-Training
  • Nurses and Nurse Practitioners
  • Physician Assistants and Other Allied Health Professionals

Learning Objectives

Upon completion of this course, the learner will be able to:

  1. Identify potential patient risk factors, including severe asthma, for COVID-19 complications in older adults in an allergy and immunology outpatient practice
  2. Discuss the treatment of a patient with moderate to severe asthma during the COVID-19 pandemic
  3. Assess and implement strategies designed to reduce COVID-19 exposure for the asthma patient and healthcare team
Available credit: 
  • 0.75 Attendance
    Attendance credit.
  • 0.75 CME
    CME credit.
Course opens: 
Course expires: 

Anil Nanda, MD FAAAAI
Asthma and Allergy Center, Lewisville and Flower Mound, TX and University of Texas-Southwestern Medical Center, Dallas, TX
Relevant relationships: None

Tolly Epstein, MD MS FAAAAI
University of Cincinnati School of Medicine and Allergy Partners of Central Indiana, Cincinnati, OH
Relevant relationships: None


Rohit Divekar, MBBS PhD
Mayo Clinic, Rochester, MN
Relevant relationships: None

Dennis K. Ledford, MD FAAAAI
University of South Florida College of Medicine and the Veterans Administration
Relevant relationships: Speaker: ALK (Topic/Product: allergic rhinitis/allergen immunotherapy); AstraZeneca (Topic: Asthma/Benralizumab); Boehringer Ingelheim (Topic/Product: COPD and asthma/tiotroprium); Genentech (Topic: Urticaria and asthma/omalizumab); Novartis (Topic: Urticaria, asthma); Sanofi/Regneron (Asthma)
Research Grant: AstraZeneca; Topic/Product: Severe asthma
Consultant: Genentec: Teaching slide development; AstraZeneca (Topic: Asthma)

Brittanie Neaves, MD
SAUSHEC/ Wilford Hall/ United States Air Force
Relevant relationships: None

Sharmilee M. Nyenhuis, MD FAAAAI
University of Illinois at Chicago
Relevant relationships: Sanofi Advisory Board

Christopher C. Randolph, MD FAAAAI
Yale University
Relevant relationships: Speaker: Boehringer Ingelheim (Topic/Product: Spiriva); Ista (Topic/Product: Pharmaceutical products); Sunvirion (Topic/Product: Pharmaceutical products); Optinose (Topic/Product: Xhance)
Research Grant: AstraZeneca (Topic/Product: Pearl study/ANDHI Benralizumab study); ALK (Topic/Product: ALK protocolMT-11/233669:ALK-Abello A/S mite SLIT in children and adolescents)
Consultant: Merck (Topic/Product: Singulair)
Honorarium/Gift: TEVA speaker,consultant,research grant (Topic/Product: Qvar/Proair); Meda speaker honorarium (Topic/Product: Dymista)
Advisory Board: Shire speaker (Topic/Product: Lanadelumab); GSK (Topic/Product: Nucala); Pharma (Topic/Product: Ruconest)
Owner of EVH unit purchased from Dr Richard Rosenthal exhibitor of EVH units (Topic/Product: EVH)

Marissa Shams, MD
Emory University School of Medicine
Relevant relationships: None

Andrew Smith, MD
Allergy Associates of Utah
Relevant relationships: None


Maria Crain, APRN CPNP
Children’s Medical Center Dallas, Dallas, TX
Relevant relationships: Aimmune: Food allergy oral immunotherapy


The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Credit claiming for this activity will expire at 11:59 pm on August 31, 2022 . Requests to claim credit on or after August 31, 2022 will be subject to an administrative fee.


To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at


Activity related questions should be directed to

Available Credit

  • 0.75 Attendance
    Attendance credit.
  • 0.75 CME
    CME credit.


Please login or register to take this course.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari.

Internet Explorer is no longer supported.